| Gene Symbol | CHMP4B |
| Full Name | Charged Multivesicular Body Protein 4B |
| Chromosome | 20q11.22 |
| Protein Type | Other |
| Target Class | Other |
| Function | The ESCRT machinery mediates the final steps of multivesicular body formation through sequential recruitment and polymerization of ESCRT-III components. |
| Mechanism of Action | CHMP4B-targeting drugs would inhibit or modulate ESCRT-III complex assembly and membrane scission, disrupting cellular degradation pathways (autophagy, lysosomal trafficking) and potentially inhibiting viral budding or cancer cell survival. Therapeutics could involve blocking protein-protein interactions within the ESCRT complex or stabilizing/destabilizing CHMP4B conformational states. |
| Primary Expression | most human tissues, with particularly high expression in:
- Eye: Lens epithelial cells and fiber cells — explaining its role in cataract
- Centr |
| Druggability | Low (0.30) |
| Clinical Stage | Phase II |
| Molecular Weight | 25 kDa |
| Amino Acids | 224 aa |
| Pathways | ESCRT-III, Extracellular Vesicle Biogenesis Modulation, autophagy, ferroptosis, mitophagy |
| UniProt ID | Q9H444 |
| Ensembl ID | ENSG00000101421 |
| GeneCards | CHMP4B |
| Human Protein Atlas | CHMP4B |
| Associated Diseases | ALS, ALZHEIMER, Alzheimer's Disease, HUNTINGTON, INFLAMMATION |
| Known Drugs/Compounds | ML-SI3 (ESCRT modulator), Spautin-1, VPS34 inhibitors (SAR405, VPS34-IN1), ALIX antagonists (investigational) |
| Interactions | RAB7A, MAPT, GBM, GPX4, KIF4A, CHMP2B |
| SciDEX Target | View Target Profile (8 clinical trials) |
| SciDEX Hypotheses | Extracellular Vesicle Biogenesis Modulation |
| KG Connections | 334 knowledge graph edges |
| Databases | GeneCardsNCBI GeneHPASTRING |